Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Patent
1996-05-21
1999-01-05
LeGuyader, John L.
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
435 911, 435325, 435366, 514 44, 536 231, 536 243, 536 245, C12Q 168, A61K 4800, C07H 7104, C12N 1586
Patent
active
058560998
ABSTRACT:
Compositions and methods are provided for the treatment and diagnosis of diseases amenable to treatment through modulation of type I IL-1 receptor mRNA expression. In accordance with preferred embodiments, oligomers are provided which are specifically hybridizable with DNA or RNA encoding type I interleukin-1 receptor. Methods of modulating type I IL-1 receptor expression and of treating animals suffering from diseases amenable to therapeutic intervention by modulating the expression of type I interleukin-1 receptor with an oligomer specifically hybridizable with DNA or RNA encoding type I interleukin-1 receptor are disclosed.
REFERENCES:
patent: 4689320 (1987-08-01), Kaji
patent: 4806463 (1989-02-01), Goodchild et al.
patent: 5013830 (1991-05-01), Ohtsuka et al.
patent: 5087617 (1992-02-01), Smith
patent: 5098890 (1992-03-01), Gewirtz et al.
patent: 5135917 (1992-08-01), Burch
patent: 5138045 (1992-08-01), Cook et al.
patent: 5166195 (1992-11-01), Ecker
patent: 5194428 (1993-03-01), Agrawal et al.
patent: 5223618 (1993-06-01), Cook et al.
patent: 5242906 (1993-09-01), Pagano et al.
patent: 5264423 (1993-11-01), Cohen et al.
patent: 5276019 (1994-01-01), Cohen et al.
patent: 5378825 (1995-01-01), Cook et al.
patent: 5585479 (1996-12-01), Hoke et al.
Rojanasakul, Antisense oligonucleotide therapeutics: drug delivery and targeting, Advanced Drug Delivery Reviews, vol. 18, pp. 115-131, 1996.
Miller et al., Gene transfer and antisense nucleic acid techniques, Parasitology Today, vol. 10(3), pp. 92-97, 1994.
Gura, Antisense has growing pains, Science, vol. 270, pp. 575-577, Oct. 1995.
Wu-Pong, Oligonucleotides: opportunities for drug therapy and research, Pharmaceutical Technology, vol. 18, pp. 102-114, Oct. 1994.
Stull et al, Antigene, ribozyme, and aptamer nucleic acid drugs: progress and prospects, Pharmaceutical Research, vol. 12(4), pp. 465-483, 1995.
Wagner, Gene inhibition using antisense oligonucleotides, Nature, vol. 372, pp. 333-335, Nov. 1994.
Stein et al., Antisense oligonucleotides as therapeutic agents--Is the bullet realy magical?, Science, vol. 261, pp. 1004-1012, Aug. 1993.
Weiss, Upping the antisense ante, Science News, vol. 139, pp. 108-109, 1991.
Milligan et al., Current concepts in antisense drug design, J. Med. Chem., vol. 36(14), pp. 1923-1937, Jul. 1993.
Burch et al., Oligonucleotides antisense to the interleukin 1 receptor mRNA block the effects of interleukin 1 in cultured murine and human fibroblasts and in mice, J. Clin. Investi., vol. 88, pp. 1190-1196, Oct. 1991.
Monia et al., Evaluation of 2'-modified oligonucleotides containing 2'-deoxy gaps as antisense inhibitors of gene expression, J. Biol. Chem., vol. 268(19), pp. 14514-14522, Jul. 1993.
Sims et al., Cloning the interleukin 1 receptor from human T cells, Proc. Natl. Acad. Sci., vol. 86, pp. 8946-8950, Nov. 1989.
Arend, "Interleukin-1 Receptor Antagonist", Adv. Immunol., 54, 167 (1993).
Chiang et al., "Antisense Oligonucleotides Inhibit Intercellular Adhesion Molecule 1 Expression by Two Distinct Mechanisms", J. Biol. Chem., 266, 18162 (1991).
Dayer and Burger, "Interleukin-1, tumor necrosis factor and their specific inhibitors", Eur. Cytokine Netw., 5, 563 (1994).
Dean et al., "Inhibitor of Protein Kinase C-.alpha. Expression in Human A549 Cells by Antisense Oligonucleotides Inhibits Induction of Intercellular Adhesion Molecule 1 (ICAM-1) mRNA by Phorbol Esters", J. Biol. Chem., 269, 16416 (1994).
Dean and McKay, "Inhibition of protein kinase C-.alpha. expression in mice after systemic administration of phosphorothioate antisense oligodeoxynucleotides", Proc. Natl. Acad. Sci., 91, 11762 (1994).
Dinarello, "The biological properties of interleukin-1", Eur. Cytokine Netw., 5, 517 (1994).
Dinarello, "The Interleukin-1 family: 10 years of discovery", The FASEB Journal, 8, 1314 (1994).
Dinarello, "Blocking Interleukin-1 in Disease", Blood Purif., 11, 118 (1993).
Colota et al., "Interleukin-1 Type II Receptor: A Decoy Target for IL-1 That Is Regulated by IL-4", Science, 261, 472 (1993).
Dinarello and Thompson, "Blocking IL-1: interleukin 1 receptor antagonist in vivo and in vitro," Immunol. Today, 12, 404 (1991).
Dinarello and Wolff, "The Role of Interleukin-1 in Disease", N. Engl. J. Med., 328, 106 (1993).
Eckstein et al., "Polynucleotides Containing 2'-Chloro-2'-deoxyribose", Biochemistry, 11, 4336 (1972).
Geiger et al., "Neutralization of interleukin-1.beta. activity in vivo with a monoclonal antibody alleviates collagen-induced arthritis in DBA/1 mice and prevents the associate acute-phase response", Clin Exp. Rheumatol., 11, 515 (1993).
Guschlbauer and Jankowski, "Nucleoside conformation is determined by the electronegativity of the sugar substitute", Nucleic Acids Res., 8, 1421 (1980).
Ikehara et al., "Recognition by restriction endonuclease EcoRI of deoxyoctanucleotides containing modified sugar moieties", Eur. J. Biochem., 139, 447 (1984).
Ikehara et al., "Polynucleotides. L. Synthesis and properties of poly (2'-chloro-2'-deoxyadenylic acid) and poly(2'-bromo-2'-deoxyadenylic acid)", Nucleic Acids Res., 4, 4249 (1978).
Inoue et al., "Synthesis and hybridization studies on two complementary nona (2'-O-methyl ribonucleotides", Nucleic Acids Research, 15, 6131 (1987).
McNamara et al., "Interleukin-1 Receptor Antibody (IL-lrab) Protection and Treatment against Lethal Endotoxemia in Mice", J. Surgical Res., 54, 316 (1993).
Rychlik and Rhoads, , "A computer program for choosing optimal oligonucleotides for filter hybridization, sequencing and in vitro amplification of DNA", Nucleic Acids Res., 17, 8543 (1989).
Sambrook et al., Molecular Cloning. A Laboratory Manual, Cold Spring Harbor Laboratory Press, 1989, vol. 2, pp. 10.59 and 11.31-11.32.
Schotanus et al., "Human Recombinant Interleukin-1 Receptor Antagonist Prevents Adrenocorticotropin, but not Interleukin-6 Responses to Bacterial Endotoxin in Rats", Endocrinology, 133, 2461 (1994).
Shibahara et al., "Inhibition of human immunodeficiency virus (HIV-1 replication of synthetic oligo-RNA derivatives", Nucleic Acids Research, 17, 239 (1987).
Sims et al., "The Two Interleukin-1 Receptors Play Different Roles in IL-1 Actions", Clin. Immunol. Immunopath., 72, 9 (1994).
Sims and Dower, "Interleukin-1 receptors", Eur. Cytokine Netw., 5, 539 (1994).
Bennett C. Frank
Dean Nicholas
Geiger Thomas
Miraglia Loren
ISIS Pharmaceuticals Inc.
LeGuyader John L.
Wang Andrew
LandOfFree
Antisense compositions and methods for modulating type I interle does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antisense compositions and methods for modulating type I interle, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antisense compositions and methods for modulating type I interle will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-861000